In a recent interview, Cathy Cutler, Ph.D., shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnostic radiopharmaceuticals to increasing patient interest in PET imaging.
A longtime researcher who has over two decades of experience in the development and assessment of radiopharmaceuticals, Cathy Cutler, Ph.D., said she is excited about the increased patient interest in positron emission tomography (PET).
“We’re at a point where patients know so much more about PET and they’re asking for this. They want to ensure their doctors have these tools to better inform their therapies. It’s exciting to see that. When you talk to patients, they’re out there now fighting with us to help make sure they have access to PET imaging, It’s not where I thought we would be about 20 years ago but it’s very exciting to see that is where we are today,” noted Dr. Cutler, the new president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Dr. Cutler said it’s important to build upon that enthusiasm in recruiting talented people into the field. Through recent surveys conducted through the SNMMI’s workforce pipeline, Dr. Cutler noted significant numbers of pending retirees so there is increasing urgency to ramp up recruiting efforts. Noting a visit to a local high school in Toronto by SNMMI leaders during the conference, Dr. Cutler said video testimonials from physicians, scientists, and technologists about the benefits of the field are also being shared with younger audiences to help spark interest.
As the director of the Medical Isotope Research Production and Development Group at Brookhaven National Laboratory in New York. Dr. Cutler said isotope availability is an ongoing challenge with demand likely to increase as more radiopharmaceuticals are utilized in patient treatment. Appropriate reimbursement is another challenge in the field, according to Dr. Cutler.
“Unfortunately, the CMS … looks at diagnostic radiopharmaceuticals as supplies, kind of like gloves so they basically bundle the costs,” posted Dr. Cutler. “It turns out those costs really don’t cover what it takes us to manufacture those drugs.”
(Editor’s note: For related content, see “SNMMI: Study Shows Viability of FAPI PET/CT for Predicting Progressive Pulmonary Fibrosis in Lung Disease Patients,” “Meta-Analysis Assesses Impact of PSMA PET/CT for Staging of Renal Cell Carcinoma” and “Study: PSMA PET/CT May Rule Out csPCa in 93 Percent of PI-RADS 3 Lesions.”)
For more insights from Dr. Cutler, watch the video below.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.